Evidence map›Paper›PMID 40866581›Full record

SynthesisJournal of cancer research and clinical oncology2025

A systematic review on the impact of delayed local therapy in patients with Ewing sarcoma of the pelvis.

Shook Fe Yap, Natacha Omer, Vivek Bhadri, Jeremy Lewin, Wayne Nicholls, Claire Carkeet, Lisa Orme, Marianne Phillips, Mark Winstanley, Smaro Lazarakis and 3 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shook Fe Yap *Oncology Services Group, Queensland Children's Hospital, South Brisbane, QLD, 4101, Australia.
Natacha Omer *Oncology Services Group, Queensland Children's Hospital, South Brisbane, QLD, 4101, Australia.
Vivek BhadriCentral Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2060, Australia.
Jeremy LewinDepartment of Cancer Medicine, Peter MacCallum Cancer Centre, Parkville, VIC, 3010, Australia.
Wayne NichollsOncology Services Group, Queensland Children's Hospital, South Brisbane, QLD, 4101, Australia.
Claire CarkeetOncology Services Group, Queensland Children's Hospital, South Brisbane, QLD, 4101, Australia.
Lisa OrmeDepartment of Cancer Medicine, Peter MacCallum Cancer Centre, Parkville, VIC, 3010, Australia.
Marianne PhillipsDepartment Oncology, Haematology and Tissue & Cellular Therapy, Perth Children's Hospital, Perth, WA, 6009, Australia.
Mark WinstanleyStarship Paediatric Blood & Cancer Centre, Grafton, 1142, Auckland, New Zealand.
Smaro LazarakisRoyal Melbourne Hospital, Parkville, VIC, 3010, Australia.
Jasmine MarAustralia and New Zealand Sarcoma Association, Melbourne, VIC, Australia.
Angela HongCentral Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2060, Australia. angela.hong@sydney.edu.au.
Julie CayrolThe Royal Children's Hospital Melbourne, Parkville, VIC, 3010, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLocal treatment of pelvic Ewing Sarcoma (EWS) is czhallenging due to complex anatomy and potential complications. Local therapy may be deferred to maintain chemotherapy dose-intensity, but the impact of this delay on outcomes remains unclear.

methodsA systematic review using the PICO model evaluated whether delayed local therapy affects long-term outcomes in localized pelvic EWS. Ovid Medline, Ovid Embase, and Cochrane Central databases were searched through June 2024. Studies were screened by two independent reviewers for quantitative and qualitative data extraction.

resultsOf 1849 studies screened, eight eligible studies including 2618 patients were identified; none were pelvic-specific. When specified, 1-18% had pelvic primaries. All studies were retrospective with substantial heterogeneity in endpoints. Seven of eight studies indicated delayed local therapy was associated with reduced event-free survival (EFS) and/or overall survival (OS). In the largest study (Lin et al.) of 1319 EWS patients, delayed local therapy > 16 weeks was associated with significantly reduced OS (HR 1.41, CI 1.11-1.80, p = 0.005).

conclusionThis systematic review highlights the importance of multidisciplinary coordinated care during initial chemotherapy to optimize local therapy timing, which may impact outcomes. Further studies are needed to assess timing significance, particularly for pelvic EWS.

Indexed as

Bone NeoplasmsPelvic BonesPelvic NeoplasmsSarcoma, EwingTime-to-TreatmentHumansEwing sarcomaGuidelinesRadiation therapyRadiotherapySarcomaSurgery

Identifiers

PMID40866581
PMCPMC12390909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.